Validation of warfarin pharmacogenetic algorithms in clinical practice

Pharmacogenomics

Volumn 13, Issue 1, 2012, Pages 21-29

  Marin Leblanc, Mélina ^a   Perreault, Sylvie ^a   Bahroun, Imen ^a,b   Lapointe, Mathieu ^a   Mongrain, Ian ^a   Provost, Sylvie ^b   Turgeon, Jacques ^a,c   Talajic, Mario ^a,b   Brugada, Ramon ^b   Phillips, Michael ^a,b   Tardif, Jean Claude ^a,b   Dubé, Marie Pierre ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Algorithms; Dose; Genotypes; Pharmacogenetics; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR; WARFARIN;

ACCURACY; ADULT; AGED; ANALYTICAL ERROR; ARTICLE; CLINICAL PRACTICE; CYP2C9 GENE; DRUG DOSE COMPARISON; DRUG INDICATION; DRUG MEGADOSE; FEMALE; GENE; GENETIC ALGORITHM; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PHARMACOGENETICS; PREDICTION; PROSTHETIC VALVE THROMBOSIS; RETROSPECTIVE STUDY; VKORC1 GENE;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ARYL HYDROCARBON HYDROXYLASES; ATRIAL FIBRILLATION; CLINICAL MEDICINE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HEART DISEASES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; WARFARIN;

EID: 83755178255     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.120     Document Type: Article

References (19)

1. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 7(2), 99-111 (2007). (Pubitemid 46567142)
2. Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005). (Pubitemid 40740552)
3. Aquilante CL, Langaee TY, Lopez LM et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79(4), 291-302 (2006).
4. Limdi NA, Beasley TM, Crowley MR et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 9(10), 1445-1458 (2008).
5. Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008).
6. Michaud V, Vanier MC, Brouillette D et al. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clin. Pharmacol. Ther. 83(5), 740-748 (2008). (Pubitemid 351556023)
7. Wadelius M, Chen LY, Lindh JD et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4), 784-792 (2009).
8. International Warfarin Pharmacogenetics Consortium; Klein TE, Altman RB, Eriksson N et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
9. Sconce EA, Khan TI, Wynne HA et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7), 2329-2333 (2005). (Pubitemid 41510803)
10. Voora D, Eby C, Linder MW et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb. Haemost. 93(4), 700-705 (2005). (Pubitemid 40485406)
11. Hillman MA, Wilke RA, Yale SH et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin. Med. Res. 3(3), 137-145 (2005).
12. Anderson JL, Horne BD, Stevens SM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22), 2563-2570 (2007). (Pubitemid 350179221)
13. Wu AH, Wang P, Smith A et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 9(2), 169-178 (2008). (Pubitemid 351566941)
14. Lubitz SA, Scott SA, Rothlauf EB et al. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J. Thromb. Haemost. 8(5), 1018-1026 (2010).
15. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet systematic review and meta-analysis. Genet. Med. 7(2), 97-104 (2005). (Pubitemid 40261834)
16. Shin J, Cao D. Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. Pharmacogenomics 12(1), 125-134 (2011).
17. Shaw PB, Donovan JL, Tran MT, Lemon SC, Burgwinkle P, Gore J. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic. J. Thromb. Thrombolysis 30(2), 220-225 (2010).
18. Roper N, Storer B, Bona R, Fang M. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J. Mol. Diagn. 12(3), 283-291 (2010).
19. Cavallari LH, Momary KM, Patel SR, Shapiro NL, Nutescu E, Viana MA. Pharmacogenomics of warfarin dose requirements in Hispanics. Blood Cells Mol. Dis. 46(2), 147-150 (2011).